Safety and Efficacy of GMX1777 in the Treatment of Refractory Solid Tumors or Lymphomas

Inclusion Criteria

• •Patients must have a histologically or cytologically confirmed solid tumor or lymphoma
• •No limitations on allowable type and amount of prior therapy.
• •Patients must have a life expectancy of greater than 8 weeks
• •Patients must have normal organ and marrow function
• •Patients must be willing to submit blood sampling for planned PK analysis
• •Patients must have the ability to understand and willingness to sign a written informed consent form